Safety and efficacy of Daclatasvir and sofosbuvir with and without ribavirin in patients with chronic hepatitis C infection and severe liver disease: results from a European Compassionate use Program
Latest Information Update: 12 May 2016
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
Most Recent Events
- 12 May 2016 New trial record
- 17 Apr 2016 Results presented at The International Liver Congress 2016